Abstract: Described herein are quinoline compounds useful for, among other things, inhibition of the proteasome and for treatment of cancer and inflammation.

Abstract: The disclosure relates to compounds of the formulae (I), (II), (lla), (III), (IV), and (IVa) and pharmaceutically acceptable salts, polymorphs, prodrugs, solvates or clathrates thereof, and pharmaceutical compositions comprising such compounds. The disclosure also relates to treating cancer with such compounds and compositions.

Abstract: Described herein are quinoline compounds useful for, among other things, inhibition of the proteasome and for treatment of cancer and inflammation.

Abstract: Described herein are quinoline compounds useful for, among other things, inhibition of the proteasome and for treatment of cancer and inflammation.

Abstract: Described herein are quinoline compounds useful for, among other things, inhibition of the proteasome and for treatment of cancer and inflammation.

Abstract: Described herein are quinoline compounds useful for, among other things, inhibition of the proteasome and for treatment of cancer and inflammation.

Abstract: Compounds and processes for catalytic ring-opening cyclooligomerization metathesis and ring-closing metathesis of olefins are described. The compound is a molybdenum or tungsten metal (M) complex which comprises an imido ligand (N—R) bound to the M to provide an M=N—R site, an M=C reaction site wherein the C of the M=C reaction site is tethered to the R of the imido ligand via a carbon or carbon and heteroatom (NOS) chain containing 1 to 12 carbon atoms to form a ring structure, and two to four ligands (R?) bound to the M to provide two to four M-R? sites. In particular embodiments, the M-R? sites include each of the oxygens of a dialkoxide ligand or each of the nitrogens of an ?1-pyrrolyl ligand bound to the M.